MEDTOX Scientific (Nasdaq: MTOX) reported earnings on July 12. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), MEDTOX Scientific met expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share dropped.

Margins shrank across the board.

Revenue details
 MEDTOX Scientific logged revenue of $30.0 million. The two analysts polled by S&P Capital IQ expected revenue of $30.3 million on the same basis. GAAP reported sales were 7.4% higher than the prior-year quarter's $27.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.17. The two earnings estimates compiled by S&P Capital IQ predicted $0.21 per share. GAAP EPS of $0.14 for Q2 were 13% lower than the prior-year quarter's $0.16 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 42.1%, 120 basis points worse than the prior-year quarter. Operating margin was 6.3%, 150 basis points worse than the prior-year quarter. Net margin was 4.1%, 90 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $30.6 million. On the bottom line, the average EPS estimate is $0.23.

Next year's average estimate for revenue is $119.3 million. The average EPS estimate is $0.78.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 154 members out of 163 rating the stock outperform, and nine members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give MEDTOX Scientific a green thumbs-up, and one give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDTOX Scientific is underperform, with an average price target of $27.00.

Over the decades, small-cap stocks, like MEDTOX Scientific have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.